Cemre Paksoy on 'Night Nurse' and the Limits of Turkish Erotic Cinema

There is a particular kind of attention that local stardom demands, and then there is the kind that international press demands of the same face. On 8 July 2026, Variety published a profile of Cemre Paksoy, the Los Angeles-based Turkish actress known to domestic audiences for her work in the long-running hit series The Affair and the Netflix drama As the Crow Flies. The story that prompted the profile is not a Hollywood pivot. It is a BluTV original called Night Nurse, in which Paksoy plays Eleni Sadik, a lead role in what Variety describes as an erotic thriller built for a streaming audience that Turkish public broadcasters have spent decades declining to court.

Paksoy's framing of the project is worth taking at face value. Prudes, she suggests, make the best perverts. The remark is the kind of line writers tend to bury under paraphrase, but Variety ran it clean. It does two things at once: it positions Night Nurse against the more guarded register of Turkish prestige drama, and it positions Paksoy — who is, in her own way, a credentialed voice from inside that establishment — as a willing participant in crossing the line.

The role and the register

Night Nurse is built around a character with a day job the title half-explains and a private life the other half does not. Variety's profile does not dispense plot in summary form; it sits closer to the role than to the synopsis. The point that emerges is that the genre itself is the news. Erotic thrillers are not a fixture of Turkish mainstream cinema, and they are not, until recently, a fixture of Turkish streaming originals either. That they now have a lead played by a face already licensed, through domestic hits, for the country's most-watched drama platforms is the structural shift worth flagging.

The Turkey that produces The Affair and As the Crow Flies is not, on the industry's own evidence, the same Turkey that commissions an erotic thriller for BluTV. The market has learned how to do both. Paksoy is one of the first actors visible enough to be the bridge.

What the platform calculus looks like

Streaming services operating in Turkey have spent the last several years bidding against one another for the same scarce resource: a domestic subscriber base that has proven willing to subscribe to local originals rather than only to foreign catalogues. BluTV, owned by the same group that operates the pay-TV platform Turkcell TV+, has positioned itself as the more provocative of the country's local streamers, distinct from the family-register drama associated with TRT's platforms and the global-style polish of Netflix's Turkish slate. Night Nurse lands inside that commercial logic: a project designed to be talked about, to be the thing a subscriber signs up specifically to watch, and to give BluTV a flagship title that competes for headlines rather than only for hours-viewed.

Paksoy's quote lands neatly inside that calculus. It is a line that reads well in any language, on any marketing surface, and it does the work of saying this is not the Turkish television your mother watched without saying it quite that way.

The export question

The piece Variety is interested in — and the reason the profile exists at all — is the export question. Paksoy lives in Los Angeles. She is in a position to pitch Night Nurse to international buyers at a moment when Turkish drama, the so-called dizi industry, has been one of the country's most successful non-military exports, with buyers across the Middle East, Latin America, the Balkans and parts of sub-Saharan Africa carrying Turkish-produced drama into markets that no American platform has fully penetrated. An erotic thriller is a specific kind of export. It is harder to license in markets with stricter broadcast-standards regimes; it is easier to license, and more eagerly, in markets that have already cleared the genre for streaming.

There is a counter-reading worth keeping on the page. The same cultural conservatism that makes Night Nurse newsworthy inside Turkey also constrains it abroad. A title that breaks a domestic taboo is not automatically a clean sell to regulators in a dozen foreign markets. Variety's framing leans into the breaking-the-taboos angle; a sober distributor's framing would lean into the regulatory limits. Both readings hold simultaneously.

Stakes for the industry

For Turkish drama, Night Nurse is a test case with a small filmography of precedents. There have been erotic dramas on Turkish platforms before; there has not, until now, been a marquee domestic name attached to a title pitched, in print, as an erotic thriller at the BluTV end of the spectrum. If the show performs — by BluTV's metrics, which are not publicly audited — it is reasonable to expect other streamers in the country to greenlight similar projects, and to expect Turkish producers with export ambitions to start building slates that include at least one such title per year.

For Paksoy personally, the role resets her ceiling. She is no longer only a known face inside Turkey; she is now the lead of a project that English-language industry press has profiled in advance of release. That has consequences for casting, for endorsement deals inside Turkey, and for the export value of her back catalogue.

There is one matter the Variety profile does not settle, and it is the obvious one. Night Nurse has not yet been released on BluTV at the time of writing. Its performance inside Turkey, its licensing path abroad, and its actual handling of the erotic-thriller register rather than the marketed one will only become legible in the weeks and months ahead. Until then, the appropriate posture is the one Variety itself takes: report the role, quote the lead, and let the rest arrive on schedule.

— Monexus culture desk. We followed Variety's profile of Cemre Paksoy and lean on the paper's framing of the BluTV project rather than reproducing its language. Where the piece points to wider questions about Turkish drama exports, we draw the structural frame in plain editorial prose without leaning on named theorists.